JP2017533922A - 移植片対宿主病（ｇｖｈｄ）のためのクロマチン構造を調節する組成物の使用 - Google Patents

移植片対宿主病（ｇｖｈｄ）のためのクロマチン構造を調節する組成物の使用 Download PDF

Info

Publication number
JP2017533922A
JP2017533922A JP2017525115A JP2017525115A JP2017533922A JP 2017533922 A JP2017533922 A JP 2017533922A JP 2017525115 A JP2017525115 A JP 2017525115A JP 2017525115 A JP2017525115 A JP 2017525115A JP 2017533922 A JP2017533922 A JP 2017533922A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
certain embodiments
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017525115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533922A5 (enExample
Inventor
ブラッドナー，ジェームス，イー．
ブレーザー，ブルース
フリン，ライアン
チー，ジュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of JP2017533922A publication Critical patent/JP2017533922A/ja
Publication of JP2017533922A5 publication Critical patent/JP2017533922A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017525115A 2014-11-06 2015-11-06 移植片対宿主病（ｇｖｈｄ）のためのクロマチン構造を調節する組成物の使用 Pending JP2017533922A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076358P 2014-11-06 2014-11-06
US62/076,358 2014-11-06
PCT/US2015/059551 WO2016073903A1 (en) 2014-11-06 2015-11-06 Use of compositions modulating chromatin structure for graft versus host disease (gvhd)

Publications (2)

Publication Number Publication Date
JP2017533922A true JP2017533922A (ja) 2017-11-16
JP2017533922A5 JP2017533922A5 (enExample) 2018-12-13

Family

ID=55909890

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525115A Pending JP2017533922A (ja) 2014-11-06 2015-11-06 移植片対宿主病（ｇｖｈｄ）のためのクロマチン構造を調節する組成物の使用

Country Status (9)

Country Link
US (1) US20190000860A1 (enExample)
EP (1) EP3215160A4 (enExample)
JP (1) JP2017533922A (enExample)
KR (1) KR20170098808A (enExample)
CN (1) CN107249593A (enExample)
AU (1) AU2015342895A1 (enExample)
BR (1) BR112017009440A2 (enExample)
CA (1) CA2966336A1 (enExample)
WO (1) WO2016073903A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA038337B1 (ru) 2014-06-17 2021-08-11 Эпизим, Инк. Ингибиторы ezh2 для лечения лимфомы
CA2964629A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
EA201890009A1 (ru) * 2015-06-10 2018-07-31 Эпизайм, Инк. Ингибиторы ezh2 для лечения лимфомы
WO2017184999A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
BR112019014924A2 (pt) 2017-01-19 2020-03-31 St. Marianna University School Of Medicine Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
CN108685880A (zh) * 2018-04-16 2018-10-23 广东省人民医院(广东省医学科学院) Bcl-6小分子抑制剂用于制备预防或治疗cGVHD的药物
WO2020011607A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
US20220016111A1 (en) * 2018-12-21 2022-01-20 The Walter And Eliza Hall Institute Of Medical Research Methods of Treating Inflammation
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN114269748A (zh) 2019-06-05 2022-04-01 米拉蒂医疗股份有限公司 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物
CN112341390B (zh) * 2019-08-07 2022-08-23 四川大学 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
CA3249707A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH AN EZH1 AND/OR EZH2 INHIBITOR
KR20250044657A (ko) * 2022-08-09 2025-04-01 다나-파버 캔서 인스티튜트 인크. 거대고리 bcl6 분해제
WO2024211684A1 (en) * 2023-04-06 2024-10-10 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005394A1 (en) * 1999-07-16 2001-01-25 Kissei Pharmaceutical Co., Ltd. Agents inhibiting chronic rejection reactions after organ transplantation
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013067296A1 (en) * 2011-11-04 2013-05-10 GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED Method of treatment
WO2014155301A1 (en) * 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066887A2 (en) * 2006-11-30 2008-06-05 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of bcl6
KR20080107050A (ko) * 2007-06-05 2008-12-10 울산대학교 산학협력단 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
WO2012005805A1 (en) * 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
US20120014979A1 (en) * 2010-07-16 2012-01-19 Alexander Dent Use of bcl6 inhibitors for treating autoimmune diseases
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9073924B2 (en) * 2011-09-13 2015-07-07 Glaxosmithkline Llc Azaindazoles
WO2013123521A1 (en) * 2012-02-17 2013-08-22 Nexbio, Inc. Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005394A1 (en) * 1999-07-16 2001-01-25 Kissei Pharmaceutical Co., Ltd. Agents inhibiting chronic rejection reactions after organ transplantation
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013067296A1 (en) * 2011-11-04 2013-05-10 GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED Method of treatment
WO2014155301A1 (en) * 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 119, no. 5, JPN6019044298, 2012, pages 1274 - 1282, ISSN: 0004285002 *

Also Published As

Publication number Publication date
EP3215160A1 (en) 2017-09-13
EP3215160A4 (en) 2018-08-08
AU2015342895A1 (en) 2017-05-18
KR20170098808A (ko) 2017-08-30
BR112017009440A2 (pt) 2017-12-19
CA2966336A1 (en) 2016-05-12
US20190000860A1 (en) 2019-01-03
WO2016073903A1 (en) 2016-05-12
CN107249593A (zh) 2017-10-13

Similar Documents

Publication Publication Date Title
US20190000860A1 (en) Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
EP3652329B1 (en) Compounds for tau protein degradation
US11903910B2 (en) Use of metformin and analogs thereof to reduce RAN protein levels in the treatment of neurological disorders
JP2019535749A (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
US11248007B2 (en) Inhibitors of MALT1 and uses thereof
JP2019537599A (ja) Ｍａｌｔ１分解のための化合物
JP2018530554A (ja) ブロモドメイン阻害薬及びチェックポイント阻害薬による併用療法
JP2017537940A (ja) 増殖性疾患の処置に有用な融合１，３−アゾール誘導体
JP2019504890A (ja) 選択的エストロゲン受容体分解剤およびその使用
JP2011530596A (ja) ｔＲＮＡ合成酵素の阻害のためのハロフジノン類似体およびそれらの使用
WO2012006104A2 (en) Compounds and methods for treating tuberculosis infection
JP2019518006A (ja) Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ
US10865213B2 (en) Max binders as MYC modulators and uses thereof
WO2021222542A1 (en) 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of ikzf2 degraders
JP2024517789A (ja) グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用
AU2019318046B2 (en) Histone demethylase 5 inhibitors and uses thereof
EP4416152A1 (en) Small molecule modulators of glucocerebrosidase activity and uses thereof
US12246021B2 (en) Compounds for uses in pharmacological induction of HBF for treatment of sickle cell disease and ß-thalassemia
WO2026039516A1 (en) Glucosylceramide synthase inhibitors and uses thereof
WO2025193275A2 (en) Compounds for inducing biostasis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200615